9 completed, 2 active not recruiting, 2 terminated, 1 available. 7 Phase 1, 7 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 7 | Completed 5, Active not recruiting 1, Terminated 1 |
| Phase 2 | 7 | Completed 4, Active not recruiting 1, Recruiting 1, Terminated 1 |
Follow LY3023414: new trials by email Literature Review of LY3023414 trials Research Report on LY3023414
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| RESOLVE: Abemaciclib + Letrozole +/- Metformin or Gedatolisib in Endometrial Cancer Letrozole, Abemaciclib, LY3023414 - Endometrial Cancer | Phase 2 | Recruiting | Dana-Farber Cancer Institute | 110 | 2018-12-24 | 2026-06-22 |
| Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial) Biospecimen Collection, Computed Tomography, FDG-Positron Emission Tomography - Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Non-Hodgkin Lymphoma | Phase 2 | Completed | National Cancer Institute (NCI) | 18 | 2017-11-28 | 2026-04-21 |
| Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial) Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration and Biopsy - Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Non-Hodgkin Lymphoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 1377 | 2017-07-31 | 2026-11-13 |
| A Study of Abemaciclib (LY2835219) Alone or in Combination With Other Agents in Participants With Previously Treated Pancreatic Ductal Adenocarcinoma Abemaciclib, LY3023414, Gemcitabine - Pancreatic Ductal Adenocarcinoma | Phase 2 | Completed | Eli Lilly and Company | 106 | 2017-01-12 | 2019-11-20 |
| A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors LY3039478, Taladegib, Abemaciclib - Solid Tumor, Breast Cancer | Phase 1 | Terminated | Eli Lilly and Company | 94 | 2016-11-04 | 2025-08-21 |
| A Study of [¹⁴C]-LY3023414 in Healthy Participants [¹⁴C]-LY3023414 - Healthy | Phase 1 | Completed | Eli Lilly and Company | 8 | 2015-10-01 | 2015-11-23 |
| A Study of LY3023414 in Japanese Participants With Advanced Cancer LY3023414 - Neoplasm | Phase 1 | Completed | Eli Lilly and Company | 12 | 2015-09-01 | 2018-07-24 |
| Study of LY3023414 for the Treatment of Recurrent or Persistent Endometrial Cancer LY3023414 - Endometrial Cancer, Recurrent Endometrial Cancer | Phase 2 | Completed | Memorial Sloan Kettering Cancer Center | 28 | 2015-09-01 | 2023-02-22 |
| A Study of LY3023414 and Necitumumab in Squamous Lung Cancer LY3023414, Necitumumab - Non-small Cell Lung Cancer Metastatic | Phase 2 | Terminated | Eli Lilly and Company | 31 | 2015-07-01 | 2020-12-09 |
| A Study of Enzalutamide and LY3023414 in Men With Prostate Cancer LY3023414, Enzalutamide, Placebo - Prostate Cancer Metastatic | Phase 2 | Completed | Eli Lilly and Company | 142 | 2015-04-29 | 2021-05-11 |
| A Study of Prexasertib (LY2606368) With Chemotherapy or Targeted Agents in Participants With Advanced Cancer Prexasertib, Cisplatin, Cetuximab - Neoplasm Metastasis, Colorectal Neoplasms | Phase 1 | Completed | Eli Lilly and Company | 167 | 2014-06-18 | 2020-04-01 |
| A Study of Abemaciclib (LY2835219) in Combination With Another Anti-cancer Drug in Participants With Lung Cancer (NSCLC) Abemaciclib, Pemetrexed, Gemcitabine - Carcinoma, Non-small Cell Lung | Phase 1 | Completed | Eli Lilly and Company | 142 | 2014-03-28 | 2020-09-11 |
| A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread LY2835219, Letrozole, Anastrozole - Breast Neoplasms | Phase 1 | Active not recruiting | Eli Lilly and Company | 198 | 2014-03-10 | 2026-01-26 |
| A Study of LY3023414 in Participants With Advanced Cancer LY3023414, Midazolam, Fulvestrant - Advanced Cancer, Metastatic Cancer | Phase 1 | Completed | Eli Lilly and Company | 156 | 2012-07-31 | 2022-04-08 |
| Master Rollover Protocol for Continued Safety Assessment of Study Drug LY2503029, LY3023414, LY3838915 - Cancer | Available | Eli Lilly and Company | 2026-06-25 |
Breast Neoplasms (4) · Lymphoma, Non-Hodgkin (3) · Neoplasms (3) · Sarcoma (3) · Carcinoma, Non-Small-Cell Lung (2) · Central Nervous System Neoplasms (2) · Endometrial Neoplasms (2) · Ependymoma (2) · Glioma (2) · Hepatoblastoma (2) · Histiocytosis, Langerhans-Cell (2) · Medulloblastoma (2) · Neoplasm Metastasis (2) · Neuroblastoma (2) · Neuroectodermal Tumors, Primitive, Peripheral (2)
Eli Lilly and Company (11) · National Cancer Institute (NCI) (2) · Dana-Farber Cancer Institute (1) · Memorial Sloan Kettering Cancer Center (1)
United States (14) · Puerto Rico (3) · Spain (3) · Australia (2) · France (2) · Belgium (1) · Canada (1) · Denmark (1) · Israel (1) · Italy (1) · Japan (1) · Taiwan (1) · United Kingdom (1)
Donald W Parsons (1) · Panagiotis Konstantininopoulos, MD (1) · Theodore W Laetsch (1) · Vicky Makker, MD (1)
PMID 24919854, PMID 30082474, PMID 31401903, PMID 33495309, PMID 33591402, PMID 33660194, PMID 33686452, PMID 34559360, PMID 35223458, PMID 35353553, PMID 35363301, PMID 36030462, PMID 36174113, PMID 37840530, PMID 41166674, PMID 42686334
U10CA180886 (2), 2015 (1), 2016 (1)